# Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

> **NCT02210858** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (actual)

## Conditions studied

- Accelerated Phase of Disease
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Chronic Myelomonocytic Leukemia
- Chronic Phase of Disease
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- Recurrent Disease

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Tipifarnib

## Key facts

- **NCT ID:** NCT02210858
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05
- **Primary completion:** 2004-11-12
- **Final completion:** 2017-03
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2018-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02210858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02210858, "Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02210858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*